Biogen Inc.

NASDAQ Global Select
1
Very Bullish +80

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen

AI-generated analysis

Biogen Inc. (NASDAQ: BIIB) has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) for approximately $5.6 billion, consisting of an upfront payment of $41.00 per share in cash and additional contingent value rights (CVRs) tied to sales thresholds for Syfovre. The...

3
Very Bullish +78

Biogen (BIIB) Stock Surges to New 52-Week Peak on Earnings Beat and Analyst Optimism

AI-generated analysis

Biogen (BIIB) shares surged to a new 52-week peak of $225.88, driven by a strong earnings beat and renewed analyst optimism. The company reported second-quarter earnings per share of $3.60, significantly exceeding the consensus estimate of $2.94, while total revenue reached $2.74 billion against expectations...

4
Bullish +75

Biogen Zooms on Deal with TJ Biopharma

AI-generated analysis

Biogen Inc. (NASDAQ: BIIB) saw its stock price rise on Monday after the company and TJ Biopharma announced a definitive agreement for Biogen to acquire exclusive rights to felzartamab in the Greater China Region. With this new agreement, Biogen now holds worldwide exclusive rights to...

5
Very Bullish +80

Biogen to acquire Apellis in $5.6bn deal

AI-generated analysis

Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion in a transaction designed to expand its portfolio within the immunology and rare disease sectors. The deal brings two commercially available, differentiated medicines, Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection), which are expected to contribute...

6
Bullish +72

Biogen Inc. $BIIB Shares Purchased by Banque Cantonale Vaudoise

AI-generated analysis

Banque Cantonale Vaudoise increased its stake in Biogen Inc. (NASDAQ:BIIB) by 129% in the first quarter, acquiring an additional 4,466 shares to hold a total of 7,928 shares valued at $1.453 million. This move joins several other institutional investors who adjusted their positions in the...

7
Bullish +75

Alteogen Enters into a License Agreement with Biogen for Development ...

AI-generated analysis

Biogen Inc. has entered into an exclusive license agreement with Alteogen Inc., a South Korean biopharmaceutical company, to develop and commercialize subcutaneous (SC) formulations of two biologics that utilize Alteogen's ALT-B4 technology. The deal involves ALT-B4, a proprietary recombinant human hyaluronidase enzyme developed using Alteogen's...

8
Somewhat Bullish +50

Biogen, UCB lupus drug dapirolizumab pegol meets phase 3 goal

AI-generated analysis

Biogen (BIIB) and UCB announced on Monday that their investigational lupus drug, dapirolizumab pegol, successfully met its primary endpoint in a phase 3 clinical trial for systemic lupus erythematosus (SLE). The data showed that 50% of patients treated with the drug achieved a BICLA response...

9
Bullish +72

Biogen stock trades near its 52-week high on growth bets

Earnings report Financial outlook AI-generated analysis

Biogen stock traded near its 52-week high of USD 229.19 on September 24, 2026, closing at USD 228 as investors reacted to strong second-quarter financial results. The company reported Q2 revenue of USD 2.74 billion, representing a 3.4 percent increase year-over-year and significantly beating the...

10
Somewhat Bearish -25

AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug

AI-generated analysis

At the Alzheimer's Association International Conference (AAIC) 2026, Biogen presented mid-stage data from its Phase 2 trial of diranersen, an antisense oligonucleotide developed with Ionis. The study validated the anti-tau hypothesis by demonstrating a correlation between tau reduction and clinical benefit in patients with Alzheimer's...

12
Bullish +75

Biogen Gets FDA Breakthrough Designation for Spinraza Successor Salanersen

AI-generated analysis

Biogen has secured FDA breakthrough therapy designation for salanersen, an investigational drug intended to treat spinal muscular atrophy (SMA). This designation is based on positive results from a Phase 1b study involving children who had previously received gene therapy and subsequently gained critical motor functions...

14
Bullish +75

Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack

Earnings report AI-generated analysis

As Biogen (NASDAQ:BIIB) concluded its Q2 earnings season, the company emerged as a standout performer within the broader therapeutics sector, which collectively saw revenues beat consensus estimates by 8%. Biogen specifically reported quarterly revenues of $2.74 billion, representing a 3.4% year-over-year increase that significantly exceeded...

15
Bullish +75

Biogen stock heads into the open after a 2.7 percent gain

AI-generated analysis

Biogen Inc. (BIIB) shares opened higher on September 23, 2026, following a strong performance in the previous session where the stock closed at USD 224.87, representing a 2.7 percent gain. The Nasdaq-listed biotechnology company traded between USD 219.07 and USD 226.43, with volume reaching 262,187...

16
Bullish +65

Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026

AI-generated analysis

Biogen (NASDAQ:BIIB) reported better-than-expected financial results for the second quarter of calendar year 2026, with revenue reaching $2.74 billion, a 3.4% increase year-over-year. The company's non-GAAP profit per share was $3.60, significantly beating analyst consensus estimates by 75.8%. Following the announcement, Biogen's stock price rose...

17
Bullish +75

Is Biogen Stock a Buy Now That Guidance Has Been Raised?

AI-generated analysis

Biogen (NASDAQ:BIIB) reported third-quarter results that outperformed Wall Street expectations, marking a significant positive shift in investor sentiment. The company has raised its sales and profit projections for the full year 2022, providing a more optimistic financial outlook than previously anticipated. The primary driver of...

18
Slightly Bullish +15

Stocks making the biggest moves premarket: Biogen, Vertiv, GE HealthCare, Generac & more

AI-generated analysis

Biogen (BIIB) shares rose 0.7% in premarket trading after the biotechnology company reported second-quarter results that beat Wall Street consensus estimates for both revenue and earnings. The positive market reaction was further amplified by the company's decision to raise its full-year adjusted earnings per share...

19
Bearish -65

Biogen Q2 2026 Earnings Preview — July 29, Street Expects $2.10 EPS

AI-generated analysis

Biogen Inc. (BIIB) is set to report second-quarter 2026 earnings on July 29, with Wall Street anticipating a sharp decline in results. Analyst consensus estimates EPS at $2.10 and revenue at $2.46 billion, though the EPS forecast shows significant dispersion ranging from a loss of...

20
Somewhat Bullish +35

BIIB Soars: New Chief Legal Officer Appointed!

AI-generated analysis

Biogen Inc. (NASDAQ: BIIB) saw its stock rise following the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. A veteran executive with over two decades of experience at Pfizer and Vertex, Parini will oversee global legal and compliance functions under...